The main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy participants. The study will last up to 5 weeks, excluding screening.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
29
Administered SC.
Orange County Research Center
Tustin, California, United States
Clinical Pharmacology of Miami
Miami, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
Nucleus Networks
Saint Paul, Minnesota, United States
Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943
PK: AUC0-∞ of LY3437943
Time frame: Predose up to 31 days postdose
PK: Maximum observed concentration (Cmax) of LY3437943
PK: Cmax of LY3437943
Time frame: Predose up to 31 days postdose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.